The original success of Sildenafil undeniably revolutionized the drug landscape, but placing funds in companies primarily reliant on unbranded versions presents a uncertain picture. While early profits were significant, the cessation of patents and the rise of discounted alternatives have eroded sales. Thus, a thorough evaluation of current financi